Aprea Therapeutics (APRE) vs XTL Biopharmaceuticals (XTLB)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Nov 22, 2026.
Summary
XTL Biopharmaceuticals is the larger company by market cap ($3.4 million vs $3.2 million), about 1.0 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | APRE | XTLB |
|---|---|---|
| Share price | $0.229 | $1.37 |
| Market cap | $3.25M | $3.37M |
| 1-day change | -53.56% | -5.84% |
| EPS (TTM) | $-0.57 | $-0.36 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| Revenue (latest FY) | — | $451.00K |
| Net income (latest FY) | $-12.60M | $-1.03M |
| Gross margin | — | 0.67% |
| Operating margin | — | -481.60% |
| Net margin | — | -227.72% |
| 52-week high | $1.49 | $5.64 |
| 52-week low | $0.2036 | $1.37 |
| Distance from 52-week high | -84.63% | -75.71% |
| Analyst consensus | none | — |
| Avg. price target upside | +1528.82% | — |
| Average volume | 388.67K | 6.58K |
| Shares outstanding | 14.19M | 2.46M |
| Employees | 8 | 4 |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
About Aprea Therapeutics
APRE stock →Aprea Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on developing and commercializing novel synthetic lethality-based cancer therapeutics that targets DNA damage response pathways. Its lead product candidates are APR-1051, an orally bioavailable small-molecule inhibitor of WEE1 kinase that is in Phase 1 clinical trial for the treatment of patients with advanced solid tumors with biomarkers and ATRN-119, an ATR inhibitor, which is in Phase 1/2a clinical trial for solid tumor indications.
Health Care · Biotechnology: Pharmaceutical Preparations · 8 employees
About XTL Biopharmaceuticals
XTLB stock →XTL Biopharmaceuticals Ltd., a biopharmaceutical company, engages in the acquisition and development of pharmaceutical drugs for the treatment of autoimmune diseases in Israel. The company's lead drug candidate is hCDR1, which is a Phase II-ready asset for the treatment of systemic lupus erythematosus and Sjogren's syndrome.
Health Care · Biotechnology: Pharmaceutical Preparations · 4 employees
APRE vs XTLB FAQ
Which is bigger, Aprea Therapeutics or XTL Biopharmaceuticals?
XTL Biopharmaceuticals (XTLB) is larger, with a market capitalization of $3.37M compared with $3.25M for Aprea Therapeutics (APRE).
Are Aprea Therapeutics and XTL Biopharmaceuticals in the same industry?
Yes. Both are classified in the Biotechnology: Pharmaceutical Preparations industry within the Health Care sector.